Arch holding strong ahead of trial data.With Trial data coming up the company is set for a bull run but in the meantime it has enough buyer interest to hold with strong support.
Long
Arch Biopartners Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0170 USD
−1.11 M USD
0.00 USD
51.98 M
About Arch Biopartners, Inc.
Sector
Industry
CEO
Richard Gabriel Muruve
Website
Headquarters
Toronto
Founded
1983
IPO date
Oct 9, 1996
Identifiers
3
ISIN CA03938C1041
Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ACHFF is 0.6835 USD — it has decreased by −2.72% in the past 24 hours. Watch Arch Biopartners Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Arch Biopartners Inc. stocks are traded under the ticker ACHFF.
ACHFF stock has risen by 21.19% compared to the previous week, the month change is a −31.20% fall, over the last year Arch Biopartners Inc. has showed a −48.61% decrease.
ACHFF reached its all-time high on Dec 1, 2021 with the price of 4.1300 USD, and its all-time low was 0.1447 USD and was reached on Jun 11, 2014. View more price dynamics on ACHFF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ACHFF stock is 6.66% volatile and has beta coefficient of 0.32. Track Arch Biopartners Inc. stock price on the chart and check out the list of the most volatile stocks — is Arch Biopartners Inc. there?
Today Arch Biopartners Inc. has the market capitalization of 47.68 M, it has decreased by −30.86% over the last week.
Yes, you can track Arch Biopartners Inc. financials in yearly and quarterly reports right on TradingView.
Arch Biopartners Inc. is going to release the next earnings report on Mar 4, 2026. Keep track of upcoming events with our Earnings Calendar.
ACHFF net income for the last quarter is −193.69 K USD, while the quarter before that showed −177.99 K USD of net income which accounts for −8.82% change. Track more Arch Biopartners Inc. financial stats to get the full picture.
No, ACHFF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ACHFF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arch Biopartners Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arch Biopartners Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arch Biopartners Inc. stock shows the sell signal. See more of Arch Biopartners Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.